Introduction
Chronic myelogenous leukemia (CML) is a lethal hematological disorder originating from a small population of leukemia stem cells (LSCs). CML cells are characterized by the presence of the BCR-ABL oncogene, which plays a critical role in hematopoietic stem cell (HSC) transformation (1) . HSC transformation results in a vast expansion of malignant myeloid cells, which retain differentiating capacity. Leukemic cells are prone to acquire additional genetic abnormalities over time, resulting in disease progression from an initial chronic phase to an advanced accelerated phase and blast crisis (2) .
Inhibition of BCR-ABL activity with tyrosine kinase inhibitors (TKIs) is remarkably effective in inducing remission and prolonging survival in patients with CML. However, CML LSCs usually persist in patients achieving remissions following TKI treatment and frequently result in leukemia relapse on discontinuation of TKI treatment (3) . As a result, most patients require continued TKI treatment to prevent relapse. However, small subsets of patients with CML that attain sustained deep remissions maintain longterm remission after discontinuing TKI treatment (4) . Patients maintaining treatment-free remissions continue to demonstrate low levels of BCR-ABL + cells when analyzed using sensitive assays, indicating persistence of BCR-ABL + stem cells (5) . The lack of leukemia recurrence in these patients suggests limited potential of residual CML long-term HSCs (LTHSCs) to regenerate leukemia and could be explained by heterogeneity in leukemogenic potential of BCR-ABL + LTHSCs, in conjunction with restriction of leukemic LTHSC growth by microenvironmental and/or immune factors.
Clonal heterogeneity of proliferative, self-renewal, and differentiation properties of normal HSCs has been recognized (6, 7) . However, heterogeneity of function of well-defined, oncogeneexpressing LSCs is less well studied. Previous studies have indicated that CML LSCs have a phenotype that is similar to that of normal LTHSCs (8) . As with normal human LTHSCs, LSCs from patients with CML share the CD34 +
CD38
-CD90 + phenotype (8) . CML LSCs demonstrate enhanced proliferation, reduced apoptosis, and increased differentiation in vitro compared with normal LTHSCs. Although human CML LSCs regenerate leukemic cells when transplanted into immunodeficient mice, engraftment levels are low and recipient mice do not develop leukemia, limiting the utility of this approach to study in vivo CML LSC growth. We therefore used an inducible transgenic mouse model of CML in which the BCR-ABL gene is expressed under the control of a tetracycline-regulated 3′ enhancer of the stem cell leukemia (SCL) gene to study CML LSCs in greater detail (9, 10 Chronic myelogenous leukemia (CML) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR-ABL fusion gene. However, BCR-ABL-expressing LTHSCs are heterogeneous in their capacity as leukemic stem cells (LSCs). Although discrepancies in proliferative, self-renewal, and differentiation properties of normal LTHSCs are being increasingly recognized, the mechanisms underlying heterogeneity of leukemic LTHSCs are poorly understood. Using a CML mouse model, we identified gene expression differences between leukemic and nonleukemic LTHSCs. Expression of the thrombopoietin (THPO) receptor MPL was elevated in leukemic LTHSC populations. Compared with LTHSCs with low MPL expression, LTHSCs with high MPL expression showed enhanced JAK/STAT signaling and proliferation in response to THPO in vitro and increased leukemogenic capacity in vivo. Although both G 0 and S phase subpopulations were increased in LTHSCs with high MPL expression, LSC capacity was restricted to quiescent cells. Inhibition of MPL expression in CML LTHSCs reduced THPO-induced JAK/STAT signaling and leukemogenic potential. These same phenotypes were also present in LTHSCs from patients with CML, and patient LTHSCs with high MPL expression had reduced sensitivity to BCR-ABL tyrosine kinase inhibitor treatment but increased sensitivity to JAK inhibitors. Together, our studies identify MPL expression levels as a key determinant of heterogeneous leukemia-initiating capacity and drug sensitivity of CML LTHSCs and suggest that high MPL-expressing CML stem cells are potential targets for therapy.
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells
Results
Heterogeneity in leukemia-initiating capacity of CML LTHSCs. Our previous studies using the SCL-tTA/BCR-ABL mouse model of CML indicate that long-term repopulation and leukemia-initiating capacity after transplantation is restricted to cells with the LTHSC LTHSCs (11, 12) . However, the frequency of BCR-ABL + cells with LTHSC phenotype with leukemia-initiating capacity is significantly lower than that of those with long-term engrafting capacity (11) . This observation suggests that CML LTHSCs may be heterogeneous and that only a small proportion of LTHSCs with longterm engrafting capacity have leukemia-initiating capacity.
In the current study, we analyzed gene expression patterns associated with the leukemia-initiating capacity of BCR-ABLexpressing LTHSCs using the transgenic BCR-ABL mouse model of CML. The results led us to evaluate the relationship of expression of the thrombopoietin (THPO) receptor MPL with leukemia- Red spots represent the mice that were sick and euthanized or found dead. (I) LTHSCs were selected from BM of nonleukemic and leukemic recipient mice at 8 weeks after transplantation, and p-CRKL expression was analyzed by flow cytometry. Results represent mean ± SEM. Student's t test was used to assess significance. Figure 1 ; supplemental material available online with this article; doi:10.1172/ JCI79196DS1). Flow cytometry analysis of MPL expression in CML and normal stem cells revealed that, within LSK cells, the highest levels of MPL expression were seen in LTHSCs (Figure 2 , C and D). CML LTHSCs expressed lower levels of MPL compared with normal LTHSCs ( Figure 2D ). In addition, Q-RT-PCR analysis showed reduced Mpl mRNA expression in CML LTHSCs compared with that in normal LTHSCs ( Figure 2E ).
Recognizing that additional mechanisms, beyond those studied here, could also contribute to the functional heterogeneity of LSCs in CML, we compared global gene expression in LTHSCs from leukemic and nonleukemic mice using RNA sequencing (RNA-Seq). As expected, this analysis identified additional categories of genes that were differentially expressed between leukemic and nonleukemic LTHSCs. Analysis of enriched gene groups using DAVID identified significant and prominent enrichment of immune response-related genes in nonleukemic LTHSCs (Supplemental Table 1 ). Gene set enrichment analysis (GSEA) further confirmed that several gene sets related to immune response were enriched in nonleukemic LTHSCs (Supplemental Table 2 ). These observations support an association between responsiveness to immune response and the leukemogenic potential of BCR-ABLexpressing LTHSCs (Supplemental Table 1 ). GSEA also indicated enrichment of HSC maturation-related genes and downregulation of MYC target genes in nonleukemic LTHSCs (Supplemental Table 2 ). Interestingly, consistent with recent reports that PPARγ agonists can deplete quiescent CML LSCs, PPARγ-related gene sets (LAL_KO_3MO_UP, LAL_KO_6MO_UP) were also observed in nonleukemic LTHSCs (17) .
Enhanced leukemogenic capacity of LTHSCs selected for high MPL expression. We next used flow cytometry to select BM LTHSCs with high and low levels of cell surface MPL expression (highest and lowest 20%; MPL hi and MPL lo , respectively) from BCR-ABL and control mice ( Figure 3A ). Differential Mpl mRNA expression was confirmed by Q-RT-PCR ( Figure 3B ). BCR-ABL and normal MPL hi LTHSCs generated significantly higher cell numbers in suspension culture (Supplemental Figure 2A) and increased colony numbers in colony-forming cell (CFC) assays (Supplemental Figure 2B ) when cultured with THPO compared with MPL lo LTHSCs. In addition, BCR-ABL MPL hi LTHSCs also showed markedly increased cell expansion and CFC potential compared with normal MPL hi LTHSCs. We did not observe significant differences in apoptosis between MPL hi and MPL lo LTHSCs from BCR-ABL and normal mice (Supplemental Figure 2C) (11) . Limiting dilution studies showed that the frequency of cells with LTHSC phenotype with long-term engraftment capacity was approximately 10-fold higher than that of those with leukemia-initiating capacity, suggesting that only a subfraction of long-term engrafting cells have LSC capacity (11) . To further evaluate heterogeneity in LSC potential, SCL-tTA/BCR-ABL mice were crossed with GFP-expressing mice to allow tracking of donor cells, and 200 GFP + donor LTHSCs per mouse were transplanted into a cohort of congenic FVBN mice. Recipient mice were followed for engraftment of GFP + cells and development of CML. We observed that primary recipients demonstrated variable levels of donor cell engraftment and leukocytosis. Since leukemia development in this mouse model usually takes place within 8 weeks, and mice that develop leukemia usually become sick or die within this period of time, for practical reasons, mice were followed for up to 8 weeks after transplant in this experiment (11) . Eleven of twenty recipient mice developed leukocytosis characteristic of CML associated with high levels of donor cell engraftment ("leukemic mice"), whereas nine mice showed long-term engraftment of GFP + cells without development of leukocytosis ("nonleukemic mice") ( Figure 1 , A-C). There was a significant correlation between high wbc count in recipient mice and high GFP + donor cell engraftment (r 2 = 0.74, P < 0.001). GFP + LTHSCs were selected from primary recipients at 8 weeks after transplant and transplanted into secondary recipient mice at 200 cells per mouse. There was a trend toward a higher number of GFP + LTHSCs being obtained from leukemic mice compared with that from nonleukemic mice ( Figure 1D ). Seven of seventeen mice receiving cells from leukemic mice developed CML after the second transplant, whereas none of the mice receiving cells from nonleukemic mice developed CML (Figure 1 , E-H). These observations suggest that the distinction between LTHSCs with leukemogenic versus nonleukemogenic capacity is maintained with serial transplantation. LTHSCs from both nonleukemic and leukemic recipient mice showed increased p-CRKL expression, indicating evidence for BCR-ABL activity in both populations ( Figure 1I ).
Differential gene expression in leukemogenic LTHSCs. LTHSCs isolated from leukemic and nonleukemic primary recipients were analyzed for expression of a panel of HSC regulatory genes by multiplex quantitative RT-PCR (Q-RT-PCR). Genes were selected to reflect regulatory mechanisms of known importance, including Wnt signaling (Fzd7, Ppard, Ccnd1), Hedgehog signaling (Gli1, Gli2, Ptchd1), Notch signaling (Hes1), and SIRT1 and p53 signaling activity (Sirt1, p53, p16, p21, Mdm2, Bax, Puma, Noxa, necdin, Gfi1, DR5). We also selected other stem cell regulatory genes (Myc, Bmi1, Pten, Foxo1), genes involved in niche interactions (Cxcr4, Tie2, Mpl, Cdh2, Itga4, Cd47), BCR-ABL, and housekeeping genes (actin, B2m, Hprt1). Using hierarchical clustering, LTHSCs from leukemic mice clustered separately from those from nonleukemic mice (Figure 2A ). We observed significant differences in expression of Mpl (P < 0.001), Myc (P < 0.001), Cd47 (P < 0.001), Pten (P < 0.01), Sirt1 (P < 0.001), Ptch1 (P < 0.001), and Tie2 (P < 0.001) ( Figure 2B ). BCR-ABL expression was not significantly different in LTHSCs from mice with leukemia compared with that in LTHSCs without leukemia. Given the importance of THPO/MPL interactions in maintenance of normal HSCs, we focused further attention on the relationship of increased Mpl expression with Results represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. 2-way ANOVA was used to assess significance. Pyronin hi (proliferating) (H and I) CD45.1 CML and (J) normal MPL hi LTHSCs were selected by flow cytometry and transplanted into CD45.2 recipients (100 cells per mouse, 10 mice per group). Engraftment in PB was monitored as shown every 4 weeks for 16 weeks or until mice developed CML or had to be euthanized. Results represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. 2-way ANOVA was used to assess significance. Results represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Student's t test was used to assess significance. 
MPL hi LTHSCs show enhanced expression of megakaryocytic lineage genes and a distinct pattern of HSC and cell cycle gene expression.
The lack of expression of CD229 is a marker of LTHSCs that are more quiescent and have high myeloid regenerative potential (18) . BCR-ABL + MPL hi LTHSCs showed lower CD229 expression compared with MPL lo LTHSCs, suggesting that they may represent a more primitive LTHSC subpopulation ( Figure  4A and Supplemental Figure 3A) . However, CD229 expression was similar in normal MPL hi and MPL lo LTHSCs. Since MPL is the receptor for THPO, the primary extrinsic regulator for platelet differentiation, we also evaluated expression of two other platelet-lineage-related genes, Cd41 and Vwf, in MPL hi LTHSCs. LTHSCs expressing these genes demonstrate enhanced platelet reconstitution, long-term myeloid lineage bias, and self-renewal (19, 20) . We observed higher cell surface expression of CD41 on MPL hi LTHSCs compared with that on MPL lo LTHSCs from both BCR-ABL and control mice ( Figure 4B and Supplemental Figure  3B ). We also observed increased mRNA expression of Mpl ( Figure  4C Figure 4G) . Transplanting normal LTHSCs expressing MPL shRNA into congenic recipients also resulted in markedly reduced donor cell engraftment in PB compared with controls ( Figure 5F ) and reduced donor cell engraftment in BM and spleen at 16 weeks (Supplemental Figure 4H) . MPL shRNAexpressing LTHSCs engrafted in mice were confirmed to have reduced Mpl mRNA expression in vivo ( Figure 5G ). MPL knockdown significantly reduced the frequency of LTHSCs in G 0 as well as in S/G 2 /M in vivo ( Figure 5H ). On the other hand, no significant difference in apoptosis was seen in vivo ( Figure 5I ). These observations indicate a complex role for MPL in regulating CML LTHSC quiescence as well as transition through cell cycle in vivo.
We analyzed the effect of MPL knockdown on p-STAT3 and p-STAT5 expression in BCR-ABL LTHSCs. Expression of p-STAT3 and p-STAT5 peaked at 30 minutes following exposure to THPO (10 ng/ml) ( Figure 6, A and B) . Knockdown of MPL expression resulted in reduced THPO-stimulated p-STAT3 and p-STAT5 expression in BCR-ABL LTHSCs ( Figure 6, A and B) . MPL shRNAexpressing LTHSCs were analyzed for expression of genes associated with THPO signaling using multiplex Q-RT-PCR. We observed significantly reduced expression of STAT target genes, including Bcl-XL, Myc, Pim1, Osm, and Hif2a, in LTHSCs with MPL knockdown compared with that in control LTHSCs from both BCR-ABL and wild-type mice (Figure 6 , C-G) (22) . Expression of other genes associated with MPL signaling, including Hoxa9, Hoxb4, and Tie2, was also reduced in MPL shRNAexpressing LTHSCs from normal, but not BCR-ABL, mice ( Figure  6 , H-J). Expression of the megakaryocytic lineage genes Vwf and Cd41 was not significantly affected by MPL knockdown ( Figure  6 , K and L). In addition, we observed reduced expression of cell cycle regulatory genes, Cdkn1b, Cdkn1c (also known as p57), and Cdkn2d, following MPL knockdown in normal LTHSCs, consistent with previous reports of reduced levels of these genes Results represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Student's t test was used to assess significance.
LTHSC-derived human cells engrafted in BM of NSG mice (Supplemental Figure 5D ). (Figure 7 , M and N, and Supplemental Figure 5E) .
Human MPL hi LTHSCs show reduced sensitivity to nilotinib. We evaluated the effect of treatment with the TKI nilotinib (NIL) on selected human MPL hi and MPL lo LTHSCs. Although NIL treatment inhibited growth ( Figure 8A ) and CFC capacity ( Figure 8B) hi and MPL lo human CML LTHSCs were cultured with THPO in the presence of AZD1480 (a JAK inhibitor) and PD0325901 (a MEK inhibitor). Evaluation of p-ERK, p-STAT3, and p-STAT5 by phospho-flow analysis confirmed inhibition of JAK/STAT and MEK signaling in AZD1480-and PD0325901-treated cells, respectively ( Figure  8E ). Treatment with either AZD1480 or PD0325901 resulted in significantly reduced cell growth ( Figure 8F ) and CFC capacity ( Figure 8G ) of MPL hi and MPL lo LTHSCs, with significantly greater inhibition seen after AZD1480 treatment compared with that after PD0325901 treatment. Treatment with AZD1480 resulted in significantly increased apoptosis of MPL hi but not MPL lo LTHSCs ( Figure 8H ) and inhibited cell cycling of both MPL hi and MPL lo LTHSCs ( Figure 8I ), whereas treatment with PD0325901 did not significantly increase apoptosis in either MPL hi or MPL lo LTHSCs ( Figure 8H ), modestly inhibited cycling of MPL hi LTHSCs, and did not significantly inhibit cycling of MPL lo LTHSCs ( Figure 8I ). These results indicate a role for both JAK/STAT and MAPK signaling in MPL-mediated regulation of cell cycling in CML LTHSCs but suggest a larger role for JAK/ STAT signaling in MPL-mediated antiapoptotic effects and enhanced cell growth.
Discussion
There is an increasing appreciation that HSCs demonstrate heterogeneity in proliferative, self-renewal, and differentiation properties at a clonal level, reflecting a complex interaction of intrinsic and extrinsic factors (6) . On the other hand, heterogeneity of function of oncogene-transformed stem cells in leukemia has not been well studied. In this study, we evaluated gene expression Figure 5C ). However, BCR-ABL expression was similar in CML MPL hi and MPL + cells in PB, BM, and spleens at 4 weeks and 16 weeks from (M and N) normal and (K and L) CML LTHSCs. Results represent mean ± SEM of results from 4 to 13 patients with CML. *P < 0.05; **P < 0.01; ***P < 0.001. 2-way ANOVA was used to assess significance.
CML MPL
hi LTHSCs also demonstrate low expression of CD229, a LTHSC phenotype associated with increased quiescence and greater myeloid regenerative potential (18) .
Murine CML and normal MPL hi LTHSCs demonstrate increased proportions of quiescent G 0 cells associated with increased expression of Cdkn2c and Cdkn2d. However, an increase in S phase cells was also observed, suggesting that MPL hi LTHSC population also contains an actively cycling subset of cells. Inhibition of MPL expression inhibited leukemogenicity of CML LTHSCs, suggesting that, besides identifying LTHSCs with enhanced leukemogenic potential, enhanced MPL expression directly contributes to CML LTHSC self-renewal and regenerative capacity. MPL inhibition also reduced engraftment of normal LTHSCs, consistent with previous studies, showing that THPO signaling through MPL regulates maintenance as well as after transplant expansion of HSCs (13, 23, 24) . MPL-deficient mice have reduced HSC frequency and competitive repopulating capacity (15) . Normal HSCs transplanted into Thpo -/-recipient mice show markedly reduced expansion (14) . Our results suggest that, in addition to its known role in normal HSCs, THPO/MPL signaling also plays an important role in maintenance and expansion of CML LSCs. The effects of THPO/MPL signaling on cell cycle are complex. In vivo THPO administration leads initially to an increase in quiescence and upregulation of CDK inhibitor expression, followed by increased cycling. In contrast, THPO exposure in vitro increases cycling of quiescent HSCs (25) . Our results indicate that THPO/ MPL signaling has similarly complex effects on CML LTHSC cell cycling. MPL knockdown in murine BCR-ABL + LTHSCs reduced cell cycling in vitro and in vivo but also reduced LTHSC quiescence in vivo. These results suggest a dual role for MPL signaling both in maintaining a quiescent LSC population and in promoting LSC cycling and leukemic cell expansion. Importantly, longterm engraftment and leukemia-initiating capacity were enriched within the quiescent subpopulation of MPL hi LTHSCs. Both murine and human CML LTHSCs show enhanced THPO-stimulated STAT3/5 activation. Knockdown of MPL expression in murine CML and normal LTHSCs resulted in reduced THPO-stimulated STAT3/5 activation, with reduced expression of STAT target genes Bcl-XL, Myc, Pim1, Osm, and Hif2a. MPL knockdown did not alter expression of the megakaryocytic lineage genes Cd41 and Vwf, suggesting that the expression of platelet-related genes is not dependent on MPL signaling. Although the effects of MPL knockdown on downstream genes were similar in CML and normal LTHSCs, several differences were also noted. For example, knockdown of MPL expression resulted in reduced expression of Hoxa9 and Hoxb4 in normal LTHSCs, consistent with previous reports of reduced expression of several Hox genes in HSCs from Thpo -/-mice. On the other hand, Hox gene expression was not altered in CML LTHSCs, suggesting that they may not play a critical role in MPL regulation of LSC function. MPL knockdown reduced Cdkn1b, Cdkn1c, and Cdkn2d in normal LTHSCs, consistent with previous studies showing increased HSC cycling and decreased expression of CDK inhibitors after exposure to neutralizing anti-MPL antibodies and in Thpo -/-mice. In contrast, MPL knockdown reduced only Cdkn1c in CML LTHSCs, indicating that MPL interacts differently with the cell cycle regulatory machinery in leukemic patterns associated with heterogeneity in leukemogenic capacity of BCR-ABL-expressing LTHSCs. Evaluation of differential expression of a preselected group of genes, of known importance in stem cell function, in mediating LTHSC heterogeneity led to the identification of increased expression of the THPO receptor MPL in murine BCR-ABL + LTHSCs with leukemogenic potential compared with those without leukemogenic potential. Murine and human BCR-ABL-expressing LTHSCs selected for higher MPL expression showed enhanced in vitro expansion and increased leukemia-initiating capacity in vivo compared with those with lower MPL expression. Finally, human CML LTHSCs with higher MPL expression demonstrated reduced sensitivity to the BCR-ABL TKI NIL but increased sensitivity to a JAK inhibitor. These results identify MPL expression as a marker as well as a key regulator of leukemogenic potential and drug sensitivity of CML LTHSCs. It is recognized that additional genes beyond those studied here could contribute to the functional heterogeneity of LSCs in CML. Indeed, RNA-Seq analysis identified that gene expression patterns associated with the immune response were downregulated in BCR-ABL + LTHSCs from mice that developed leukemia compared with nonleukemic mice, suggesting a potential role for the immune response in regulating the leukemogenic potential of BCR-ABL + LTHSCs. This observation opens up further avenues for future investigation.
Increased MPL expression was also associated with enhanced proliferation and engraftment capacity of normal murine and human LTHSCs. These results are consistent with previous reports that stem cell activity segregated with MPL expression in murine fetal stem cell-enriched populations (16) . Murine CML and normal MPL hi LTHSCs demonstrate increased expression of megakaryocytic lineage genes and a distinct pattern of HSC and cell cycle gene expression. This gene expression pattern suggests similarities to a recently described molecularly and functionally distinct subset of "platelet-primed" LTHSCs, which express vWF and other platelet-specific genes, and appear to be at the apex of the HSC hierarchy (19) . Platelet-primed HSCs are characterized by dependence on THPO for maintenance, platelet-regenerating capacity, long-term myeloid lineage bias, enhanced self-renewal capacity, and capability of generating lymphoid-biased HSCs. Similarly, LTHSCs expressing the platelet integrin CD41 also exhibit megakaryocyte gene priming, show marked myeloid bias, and possess long-term repopulation and serial transplantation capacity (20) . Therefore, the enhanced leukemogenic capacity of MPL hi LTHSCs could be related to their being derived from platelet-primed LTHSCs with increased self-renewal capacity and myeloid bias. hi and MPL lo LTHSCs were cultured with and without THPO in the presence of the JAK inhibitor AZD1480 or the MEK inhibitor PD0325901, and p-ERK, p-STAT3, and p-STAT5 expression was checked by flow cytometry. CML MPL hi and MPL lo LTHSCs were cultured with JAK or MEK inhibitor for 3 days and (F) cell growth, (G) CFC capacity, (H) apoptosis, and (I) cell cycle were checked. *P < 0.05; **P < 0.01; ***P < 0.001. 2-way ANOVA was used to assess significance. jci.org Volume 126 Number 3 March 2016 kemia development indicates that such LTHSCs have impaired leukemogenic capacity, possibly related to reduced self-renewal and proliferation (40, 41) . This implies that leukemogenic LTHSCs are critical targets for therapeutics, whereas minimal residual disease resulting from persistence of nonleukemogenic LTHSCs may not confer risk of relapse. Our results may also have relevance for explaining the detection of BCR-ABL transcripts in blood cells from healthy individuals without CML (42) . The cell context in which BCR-ABL gene mutation occurs is likely to be critical, and the mutation may need to occur in LTHSCs with high self-renewing potential in order to induce leukemia. THPO receptor agonist drugs are effective in the treatment of refractory immune thrombocytopenia and are being investigated for treatment of BM failure syndromes (43, 44) . However, clonal evolution or progression to AML has been recognized as a concern when using THPO receptor agonists in patients with aplastic anemia and MDS, and registry data suggests a possible association between these agents and AML in patients with immune thrombocytopenia (45) . Our findings that TPO signaling can sustain or expand CML LTHSCs indicate the need for caution in using these agents in patients with or at risk for leukemia, with careful evaluation of their risks and benefits.
Methods
Mice. Inducible transgenic SCL-tTA/BCR-ABL mice in the CD45.1 FVB/N background were maintained with administration of tetracycline in the drinking water (0.5 g/l) (10 (27) . However, JAK2 appears to be important for STAT activation downstream of cytokine signaling in CML cells (28) . Increased baseline and THPO-stimulated p-STAT3 and p-STAT5 expression in CML MPL hi LTHSCs compared with that in normal MPL hi LTHSCs suggests that BCR-ABL can potentiate MPL signaling through the JAK/STAT signaling pathway. Since receptor internalization plays a necessary role in MPL signaling, enhanced MPL signaling may explain in part reduced receptor expression seen in murine CML LTHSCs compared with that in normal LTHSCs (29) . Altered MPL signaling is also a feature of BCR-ABL-negative myeloproliferative neoplasms, in which, in addition to more commonly seen JAK2 V617F mutations, MPL mutations leading to constitutive activation of JAK2, STAT3, and STAT5 signaling are often observed (30) . In AML LSC, high STAT signaling activity is associated with poor prognosis (31, 32) .
Resistance of CML LSCs to elimination by TKI treatment is an important area of investigation in CML. LSC persistence and consequent risk of relapse leads to life-long dependence on TKI treatment to maintain remission in the bulk of patients with CML. We found that human CML MPL hi LTHSCs demonstrated reduced TKI-mediated inhibition of growth and resisted TKImediated inhibition of survival compared with MPL lo LTHSCs. TKI resistance may be related in part to THPO-induced JAK/ STAT activation in CML cells. Induction of LSC quiescence by THPO signaling may further contribute to resistance of MPL hi LTHSCs to TKI. In addition, signaling through the TPHO/MPL/ BCL-XL pathway has been shown to contribute to survival and self-renewal in human RUNX1-ETO-induced leukemia (33, 34) . Finally, THPO may also potentiate resistance to antileukemia treatment by enhancing DNA repair, which could limit cytotoxicity of DNA-damaging treatments (35) . Our findings support further investigation of approaches to antagonize MPL signaling as a potential therapeutic strategy to eliminate leukemia-initiating LTHSCs. Such approaches could include specific neutralizing antibodies to MPL and inhibitors that also enhance receptor internalization and degradation or inhibition of downstream mechanisms, such as JAK/STAT signaling (36) . We have recently reported that JAK2 inhibition with ruxolitinib can enhance elimination of chronic phase CML CD34 + cells in combination with BCR-ABL TKI (37) . The present study shows that JAK2 and MEK inhibition reduced human CML MPL hi LTHSC cell cycling and cell growth. JAK2 inhibition also enhanced apoptosis of MPL hi LTHSCs. Since MPL hi LTHSCs demonstrate reduced sensitivity to BCR-ABL TKI alone, these observations provide a strong rationale for further exploration of the use of additional JAK/STAT inhibition to target CML LSC resistant to BCR-ABL TKI alone.
Our results may also be relevant to the observation that residual BCR-ABL + hematopoietic cells can be detected in patients with CML maintaining treatment-free remissions, without disease recurrence, following hematopoietic cell transplantation, interferon-α, and TKI treatment (4, 38, 39) . The long-term persistence of leukemic cells indicates the presence of BCR-ABL + LTHSCs, whereas lack of leu- ) following the manufacturer's protocol with minor modifications. Briefly, 500 pg DNA-free RNA from each sample was reverse transcribed and amplified with 13 cycles of Q-RT-PCR using SMART (switching mechanism at 5′ end of RNA template) technology. The resulting double-stranded cDNA was sheared with Covaris S220 (Covaris) followed by end repair, 3′-end adenylation, ligation of bar-coded adapters (Illumina), and 10 cycles of Q-RT-PCR to produce the final sequencing library. Library templates were prepared for sequencing using the cBot cluster generation system with the HiSeq SR Cluster Kit V4 (Illumina). Sequencing was performed using the HiSeq 2500 platform with the HiSeq SBS Kit V4 (Illumina). Real-time analysis 2.2.38 software was used for image analysis and base calling. The Bioconductor ShortRead package was used to analyze FASTQ files, and reads were aligned to the mm9 reference genome. Analysis of differentially expressed genes was performed using the Bioconductor EdgeR package. Gene function analysis was performed using DAVID Bioinformatics Resources 6.7, and GSEA was performed using GSEA software. The RNA-Seq data has been deposited in the Gene Expression Omnibus database (accession GSE76123).
Lentivirus transduction of murine LTHSCs. MPL shRNA (NM_010823, Sigma-Aldrich) and control shRNA sequences were cloned into the PPIG-U6-GFP plasmid. Lentivirus supernatants were produced and used for transduction of murine LTHSCs as previously described (47) . Briefly, BM LTHSCs from BCR-ABL or control mice (CD45.1) were cultured overnight in SFEM medium supplemented with mouse SCF (10 ng/ml) and mouse THPO (10 ng/ml). The next day, cells were resuspended in SFEM and lentivirus supernatant (multiplicity of infection = 10), supplemented with 10 ng/ml SCF, and centrifuged at 800 g for 90 minutes for transduction by spinoculation. Gene expression analysis. Total RNA was extracted from LTHSCs using the RNeasy Plus Micro Kit (Qiagen). First-strand cDNA was synthesized from 200 cells using the SuperScript III First-Strand Kit and
